Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Bilen, Mehmet Asim ^a   Subudhi, Sumit K ^a   Gao, Jianjun ^a   Tannir, Nizar M ^a   Tu, Shi Ming ^a   Sharma, Padmanee ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immune checkpoint inhibitors; Immune related adverse event; Ipilimumab; Nivolumab; Polymyositis; Rhabdomyolysis; Urothelial carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATINE KINASE; CREATININE; DOXORUBICIN; GEMCITABINE; IPILIMUMAB; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ANTIBODY; NIVOLUMAB; PEMETREXED; TROPONIN I; VINBLASTINE;

AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CYSTOSCOPY; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE STRENGTH; MYOGLOBINURIA; PERIPHERAL LUNG LESION; POLYMYOSITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; UREA NITROGEN BLOOD LEVEL;

EID: 84997161404     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0139-8     Document Type: Article

References (15)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
3. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30.
4. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35.
5. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803-13.
6. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-17.
7. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.
8. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-32.
9. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.
10. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270-1.
11. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009;36(4):518-20.
12. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16(4):589-93.
13. Yoshioka M, Kambe N, Yamamoto Y, et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol. 2015;42(10):1008-9.
14. Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015;151(2):195-9.
15. Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2(1):15-8.